REMARKS

Novelty

The Examiner has rejected Claims 1-8, 13-17 and 20 under 35 USC §102(e) as being allegedly anticipated by Tromblay et al. (USP 6,534,056).

US 6,534,056 B1 relates to TC-PTP, i.e. T cell protein tyrosine phosphatase. The authors propose to increase the TC-PTP activity to provide a protection against DNA damage.

To the contrary, the inventors of the instant US patent application propose to administer phosphotyrosine to biological material for protecting the latter from cell-damaging factors.

TC-PTC and phosphotyrosine are totally different compounds and have nothing in common. TC-PTC is an enzyme having phosphatase activity, whereas phosphotyrosine is a modified amino acid. Therefore, Tromblay et al. does not anticipate the present claims, and their rejection under 35 USC §1029(e) should be withdrawn.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: September 11, 2007

By: _____

Marina L. Gordey
Registration No. 52,950
Agent of Record
Customer No. 20995
(805) 547-5580

AMEND

4225160
090407